Noesion Radarnoesion.ai
Market2026-10-16

AstraZeneca partnered with insitro on a $1.5bn AI drug discovery deal. The collaboration targets liver and heart diseases using insitro’s Virtual Human platform. AstraZeneca will run future clinical trials from the partnership. Iambic Therapeutics raised $150m in a Nasdaq IPO at a $16 share price. Its lead drug IAM1363 is in phase 1 for HER2-positive cancers. DaltonTx received a Gates Foundation grant for AI-driven tuberculosis drug research. Danaher and NVIDIA are co-developing autonomous AI-powered labs for faster research. GSK upgraded its evaluation of Chai Discovery to a full partnership. Chai’s models generated zero-shot drug designs validated by GSK in wet-lab tests.

What it unlocks

Accelerated drug target discovery for cardiometabolic diseases using AI-powered platforms.

  • $1.5bn total partnership value
  • $40m upfront payment
  • $150m IPO raise
  • $800m+ Iambic valuation

Sources

Send this to someone who needs it

Shares the story and its sources. Nothing about you.

What does this mean for your job?

This is the story as everyone gets it. Once a week we send you the version written for your role — what changed, why it matters for the work you actually do, and one thing to try. Free while we tune it.